Table 4.
Quinolone susceptibility and identification of resistant mutants associated with different dosages of danofloxacin.
| MICs (μg/mL) |
Mutations |
|||||
|---|---|---|---|---|---|---|
| Dosages (mg/kg) | Danofloxacin | Danofloxacin + reserpine | Enrofloxacin | Enrofloxacin + reserpine | gyrA | parC |
| 0 | 0.06 | 0.03 | 0.125 | 0.03 | – | – |
| 0.6 (n = 2) | 0.25 | 0.125 | 0.5 | 0.125 | – | K53E |
| 0.8 (n = 3) | 0.25 | 0.125 | 0.5 | 0.125 | – | K53E |
| 1.25 (n = 4) | 1 | 1 | 2 | 1 | S83Y | K53E |
| 2.5 (n = 3) | 1 | 1 | 2 | 1 | S83Y | K53E |
| 3.5 (n = 1) | 0.5 | 0.5 | 1 | 0.25 | S83F | K53E |
–, No mutant was found; n, the number of tissue cages with mutant strains; gyrA, parC, the target genes of mutations in QRDRs. Reserpine concentration was at 20 μg/mL.